Key result
IV nicardipine achieves target blood pressure within 2 hours in ~77% of severe antepartum hypertension.
Why the study?
Severe hypertension during pregnancy requires prompt stabilization with intravenous antihypertensives, but it remains unknown which agent is best suited.
Does intravenous nicardipine safely and effectively reduce blood pressure in pregnant women with severe antepartum hypertension?
Observational (n=830)
Yes
Does intravenous nicardipine safely and effectively reduce blood pressure in pregnant women with severe antepartum hypertension?
Intravenous nicardipine is a highly effective and safe first-line treatment for rapidly lowering blood pressure in women with severe antepartum hypertension.
May support nicardipine for rapid BP control in severe antepartum hypertension; leaves open confirmation in randomized trials.
INTRODUCTION: Women with severe hypertension during pregnancy require prompt stabilization with a combination of magnesium sulfate and rapidly acting intravenously administered antihypertensives. It remains unknown which antihypertensive is best suited for pregnancy. The present study evaluated the intravenous use of the calcium antagonist, nicardipine. MATERIAL AND METHODS: This multicenter, retrospective case series included all pregnant women beyond 20 weeks of gestation with severe antepartum hypertension that were treated with intravenous nicardipine. PRIMARY OUTCOME MEASURES: successful treatment, time to successful treatment, and maternal safety. Severe hypertension was defined as systolic blood pressure (SBP) of 160 mm Hg or more and/or diastolic blood pressure (DBP) of 110 mm Hg or more. RESULTS: This study included 830 women. After 1 h of treatment, two-thirds of the women had SBP below 160 mm Hg and DBP below 100 mm Hg. In three out of four women, the mean arterial pressure was below 120 mm Hg. Within 2 h of treatment, 77.4% of women achieved successful treatment. In all cases, nicardipine was eventually effective. Within the first 2 h, 42.7% of women experienced temporary low DBP (ie below 70 mm Hg) without clinical consequences for the mother or fetus. In all cases, the low DBP resolved after discontinuing or reducing the dosage of nicardipine. One case of fetal distress was attributable to maternal hypotension, and a cesarean section was performed at more than 2 h after initiating therapy. During treatment, headache, nausea, and vomiting decreased significantly. CONCLUSIONS: To date, this was the largest case-series study on the use of nicardipine for treating severe antepartum hypertension in pregnancy. We found that nicardipine could effectively and safely treat this condition. Based on its high success rate and acceptable safety profile, nicardipine should be considered a first-line treatment in women with severe hypertension in pregnancy.
No takes yet. Share an insight, caveat, or question.
Bijvank et al. (2022) conducted an observational in Severe antepartum hypertension (n=830). Intravenous nicardipine was evaluated on Successful treatment (SBP < 160 mm Hg and DBP < 100 mm Hg). Intravenous nicardipine successfully reduced blood pressure to target levels in 100% of pregnant women with severe antepartum hypertension, with 77.4% achieving successful treatment within 2 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: